Theravance Biopharma (NASDAQ:TBPH) is a diversified biopharmaceutical company dedicated to discovering, developing and commercializing medicines in areas of high unmet medical need. The company focuses primarily on respiratory and immunology therapeutic areas and employs a model that integrates in-house research with strategic external partnerships. Headquartered in South San Francisco, California, Theravance Biopharma is committed to advancing novel therapies that improve the lives of patients suffering from chronic and acute diseases.
Theravance Biopharma’s commercial portfolio includes YUPELRI® (revefenacin), a once-daily, nebulized long‐acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the United States. Beyond its marketed product, the company maintains a robust pipeline of clinical-stage investigational medicines. Key programs include a selective norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension and a gut-selective JAK inhibitor for inflammatory bowel disease. The company’s approach combines medicinal chemistry, translational biology and patient‐centered clinical development to generate differentiated assets.
Originally established through a spin-out from Theravance, LLC, the company has grown through alliances with leading pharmaceutical firms and academic institutions. Collaborations have included research and development partnerships that leverage external expertise in formulation technology, global regulatory affairs and commercial distribution. While the United States serves as Theravance Biopharma’s primary market, the company has secured licensing agreements to extend its reach into Europe, Asia and Latin America, positioning its therapies for broader patient access worldwide.
Under the leadership of President and Chief Executive Officer Richard “Rick” E. Winningham, Theravance Biopharma emphasizes scientific rigor, operational discipline and patient engagement. The management team brings extensive experience in drug discovery, clinical development and commercial execution, supported by a board of directors with deep expertise in biotechnology and healthcare. As Theravance Biopharma advances its pipeline toward regulatory milestones, the company remains focused on driving long-term value through innovation and strategic growth initiatives.
